Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.7.3.3 - factor-independent urate hydroxylase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acatalasia
Catalase deficiency may complicate urate oxidase (rasburicase) therapy.
Inherited catalase deficiency: Is it benign or a factor in various age related disorders?
Acidosis
Metabolic Acidosis Alters Expression of Slc22 Transporters in Mouse Kidney.
Peracute onset of severe tumor lysis syndrome immediately after 4 Gy fractionated TBI as part of reduced intensity preparative regimen in a patient with T-ALL with high tumor burden.
[The pathophysiology, clinical signs and therapy of urate nephropathy]
Acute Kidney Injury
A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.
Acute and severe ribavirin-associated hyperuricemia and acute kidney injury: An underrecognized adverse effect.
Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
EFFICACY OF RASBURICASE THERAPY IN OBSTRUCTIVE NEPHROPATHY FROM RENAL CALCULI: A NOVEL THERAPEUTIC OPTION.
Hemolysis and methemoglobinemia secondary to rasburicase administration.
Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
Is it the right time to subject children with acute kidney injury to rasburicase trials?
Pharmacological treatment of acute and chronic hyperuricemia in kidney diseased patients.
Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?
Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.
Rasburicase for acute kidney injury.
Rasburicase for huge hepatocellular carcinoma with tumor lysis syndrome: case report.
Rasburicase for the management of tumor lysis syndrome in neonates.
Rasburicase improves hyperuricemia in infants with acute kidney injury.
Rasburicase improves hyperuricemia in patients with acute kidney injury secondary to rhabdomyolysis caused by ecstasy intoxication and exertional heat stroke.
Rasburicase improves the outcome of acute kidney injury from typical hemolytic uremic syndrome.
Rasburicase induced severe hemolysis and methemoglobinemia in a Caucasian patient complicated by acute renal failure and ARDS.
Single dose of rasburicase for treatment of hyperuricemia in acute kidney injury: a report of 3 cases.
Tumor Lysis Syndrome after Hepatic Artery Embolization in a Patient with Neuroendocrine Tumor of Unknown Primary.
Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature.
Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
Urat1-Uox double knockout mice are experimental animal models of renal hypouricemia and exercise-induced acute kidney injury.
[Tumor lysis syndrome: risk factors and treatment]
Anaphylaxis
A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties.
Anaphylactic Shock Following Repeated Rasburicase Treatment.
Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase.
Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.
Rasburicase (Elitek): a novel agent for tumor lysis syndrome.
Risk of Anaphylaxis with Repeated Courses of Rasburicase: A Research on Adverse Drug Events and Reports (RADAR) Project.
Anemia
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
[The hydrogen peroxide paradox]
Anemia, Hemolytic
Distinct mechanisms for rasburicase induced hemolytic anemia and methemoglobinemia in tumor lysis syndrome.
Hemolysis and methemoglobinemia secondary to rasburicase administration.
Hemolytic anemia due to G6PD deficiency and urate oxidase in a kidney-transplant patient.
Hemolytic anemia following rasburicase administration: a review of published reports.
Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia.
Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemia.
Rasburicase-induced haemolysis and methemoglobinemia: an ongoing issue.
Rasburicase-induced Hemolytic Anemia in an Adolescent With Unknown Glucose-6-Phosphate Dehydrogenase Deficiency.
Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.
Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm.
Rasburicase: a potent uricolytic agent.
Anemia, Sickle Cell
Hyperuricaemia in sickle cell disease.
Ankylosis
Divergent patterns of joint remodelling following effective urate-lowering therapy in tophaceous gout.
Anuria
[Anuria with hyperuricemia revealing acute leukemia. Treatment with urate oxidase]
Arteriolosclerosis
Time to target uric acid to retard CKD progression.
Arthritis
Characterization, efficacy, pharmacokinetics, and biodistribution of 5kDa mPEG modified tetrameric canine uricase variant.
Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies.
Investigation on uric acid biosensor model for enzyme layer thickness for the application of arthritis disease diagnosis.
Physiological concentrations of soluble uric acid are chondroprotective and anti-inflammatory.
Arthritis, Gouty
Hyperuricemia and urate nephropathy in urate oxidase-deficient mice.
Atherosclerosis
Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine/dimethylarginine dimethylaminotransferase 2 pathway.
Bronchial Spasm
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies.
Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.
[Bronchospasm as an allergic manifestation after intravenous injection of urate oxidase in a female patient treated for myeloma]
Burkitt Lymphoma
Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature.
Excessive elevation of serum phosphate during tumor lysis syndrome: Lessons from a particularly challenging case.
Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
Methemoglobinemia induced by rasburicase in a pediatric patient: A case report and literature review.
Carcinogenesis
Catalase and uricase studies on rats during 2-acetylaminofluorene carcinogenesis.
Carcinoma
A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase.
A study of some mitochondrial and peroxisomal enzymes in human colonic adenocarcinoma.
Peroxisomal enzymes in normal and tumoral human breast.
Carcinoma, Hepatocellular
Rasburicase for huge hepatocellular carcinoma with tumor lysis syndrome: case report.
SIRT5 promotes cell proliferation and invasion in hepatocellular carcinoma by targeting E2F1.
[Distribution, after differential centrifugation, of acid hydrolases, catalase, D-amino acid oxidase and urate oxidase in various Morris hepatomas]
Carcinoma, Ovarian Epithelial
A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase.
Cardiovascular Diseases
Update on gout: pathophysiology and potential treatments.
catalase deficiency
Catalase deficiency may complicate urate oxidase (rasburicase) therapy.
Inherited catalase deficiency: Is it benign or a factor in various age related disorders?
Dehydration
Identification of quasi-stable water molecules near the Thr73-Lys13 catalytic diad of Bacillus sp. TB-90 urate oxidase by X-ray crystallography with controlled humidity.
Dermatitis, Contact
The endogenous danger signal uric Acid augments contact hypersensitivity responses in mice.
Diabetes Insipidus
Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.
Diabetes Mellitus, Type 2
Lowering serum urate does not improve endothelial function in patients with type 2 diabetes.
Down Syndrome
Transient myeloproliferative disorder in a newborn with Down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: a case report.
Drug-Related Side Effects and Adverse Reactions
Risk of Anaphylaxis with Repeated Courses of Rasburicase: A Research on Adverse Drug Events and Reports (RADAR) Project.
Encephalitis, Japanese
Gateways to clinical trials.
Endotoxemia
Impact of uric acid on liver injury and intestinal permeability following resuscitated hemorrhagic shock in rats.
Essential Hypertension
[Role of uric acid in hypertension and in the progression of chronic renal disease.]
factor-independent urate hydroxylase deficiency
Hyperuricemia and urate nephropathy in urate oxidase-deficient mice.
Hyperuricemia causes kidney damage by promoting autophagy and NLRP3-mediated inflammation in rats with urate oxidase deficiency.
Mouse paracentric inversion In(3)55Rk mutates the urate oxidase gene.
Two independent mutational events in the loss of urate oxidase during hominoid evolution.
Uricase deficiency causes mild and multiple organ injuries in rats.
Fetal Resorption
Oxonic acid and fetal development: II.Teratogenicity in rats.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.
Hemolysis and methemoglobinemia secondary to rasburicase administration.
Hemolytic anemia due to G6PD deficiency and urate oxidase in a kidney-transplant patient.
Methaemoglobinaemia in a G6PD-deficient child treated with rasburicase.
Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase.
Methemoglobinemia induced by rasburicase in a pediatric patient: A case report and literature review.
Rare Case of Transcutaneous Oxygen Desaturation in a Cancer Patient: A Case Report and Diagnostic Approach for a Recurrent Problem.
Rasburicase : a review of its use in the management of anticancer therapy-induced hyperuricaemia.
Rasburicase Causing Severe Oxidative Hemolysis and Methemoglobinemia in a Patient with Previously Unrecognized Glucose-6-Phosphate Dehydrogenase Deficiency.
Rasburicase induced severe hemolysis and methemoglobinemia in a Caucasian patient complicated by acute renal failure and ARDS.
Rasburicase-induced haemolysis and methemoglobinemia: an ongoing issue.
Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6-Phosphate Dehydrogenase Deficiency.
Rasburicase-induced methemoglobinemia in two African-American female patients: an under-recognized and continued problem.
Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.
Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm.
Rasburicase: a potent uricolytic agent.
Spotlight on rasburicase in anticancer therapy-induced hyperuricemia.
[A severe G6PD deficiency revealed during a chemotherapy protocol including rasburicase]
Glucosephosphate Dehydrogenase Deficiency
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.
Hemolysis and methemoglobinemia secondary to rasburicase administration.
Hemolytic anemia due to G6PD deficiency and urate oxidase in a kidney-transplant patient.
Methaemoglobinaemia in a G6PD-deficient child treated with rasburicase.
Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase.
Methemoglobinemia induced by rasburicase in a pediatric patient: A case report and literature review.
Rare Case of Transcutaneous Oxygen Desaturation in a Cancer Patient: A Case Report and Diagnostic Approach for a Recurrent Problem.
Rasburicase : a review of its use in the management of anticancer therapy-induced hyperuricaemia.
Rasburicase Causing Severe Oxidative Hemolysis and Methemoglobinemia in a Patient with Previously Unrecognized Glucose-6-Phosphate Dehydrogenase Deficiency.
Rasburicase induced severe hemolysis and methemoglobinemia in a Caucasian patient complicated by acute renal failure and ARDS.
Rasburicase-induced haemolysis and methemoglobinemia: an ongoing issue.
Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6-Phosphate Dehydrogenase Deficiency.
Rasburicase-induced methemoglobinemia in two African-American female patients: an under-recognized and continued problem.
Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.
Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm.
Rasburicase: a potent uricolytic agent.
Spotlight on rasburicase in anticancer therapy-induced hyperuricemia.
[A severe G6PD deficiency revealed during a chemotherapy protocol including rasburicase]
Glycogen Storage Disease Type II
Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies.
Gout
A Case Report of Immunosuppressant Medication?Associated Polyarticular Tophaceous Gout Successfully Treated Using the Polyethylene Glycol?Conjugated Uricase Enzyme Pegloticase.
A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable?
A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.
A radiochemical-high-performance liquid chromatographic assay for urate oxidase in human plasma.
A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties.
Cloning, expression and purification of recombinant uricase enzyme from Pseudomonas aeruginosa Ps43 using Escherichia coli.
Cloning, purification, and partial characterization of Bacillus subtilis urate oxidase expressed in Escherichia coli.
Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout.
Comparison of modification of a bacterial uricase with N-hydroxysuccinimide esters of succinate and carbonate of monomethoxyl poly(ethylene glycol).
Comparison of Two Corticosteroid Pre-Infusion Regimens for Pegloticase in the United States: A Retrospective Analysis in Community Rheumatology Practices.
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene) glycol (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
Development of Therapeutic Chimeric Uricase by Exon Replacement/Restoration and Site-Directed Mutagenesis.
Dual energy computed tomography for quantification of tissue urate deposits in tophaceous gout: help from modern physics in the management of an ancient disease.
Economic analysis of uricase production under uncertainty: Contrast of chromatographic purification and aqueous two-phase extraction (with and without PEG recycle).
Effect of surfactants and inducers on increased uricase production under submerged fermentations (SMF) by Bacillus cereus.
Enhancement of Pharmaceutical Urate Oxidase Thermostability by Rational Design of De Novo Disulfide Bridge.
Enzyme-entrapped mesoporous silica for treatment of uric acid disorders.
Evolutionary history and metabolic insights of ancient mammalian uricases.
Gout is on the increase in New Zealand.
Gout therapeutics: new drugs for an old disease.
Hyperuricemia and urate nephropathy in urate oxidase-deficient mice.
Impact of pegloticase on patient outcomes in refractory gout: current perspectives.
Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.
Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
ISOLATION, SCREENING AND PRODUCTION STUDIES OF URICASE PRODUCING BACTERIA FROM POULTRY SOURCES.
Learning how and when to employ uricase as bridge therapy in refractory gout.
Management of acute and chronic gouty arthritis: present state-of-the-art.
Mathematical modeling for bioprocess optimization of a protein drug, uricase, production by Aspergillus welwitschiae strain 1-4.
Medicinal Plants as a Drug Alternative Source for the Antigout Therapy in Morocco.
Molecular Elucidation of a Urate Oxidase from Deinococcus radiodurans for Hyperuricemia and Gout Therapy.
Multivalent Albumin-Neonatal Fc Receptor Interactions Mediate a Prominent Extension of the Serum Half-Life of a Therapeutic Protein.
New insight into the molecular mechanism of the trehalose effect on urate oxidase stability.
Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice.
Pathophysiology, clinical presentation and treatment of gout.
Pegloticase for treating refractory chronic gout.
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.
Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations.
Pegloticase treatment of chronic refractory gout: Update on efficacy and safety.
Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout.
Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
Pharmacokinetics and pharmacodynamics of pegloticase in patients with end-stage renal failure receiving hemodialysis.
Pharmacokinetics of Polyethylene Glycol-Modified Canine Uricase Following Single and Multiple Intravenous Injections in Cynomolgus Monkeys.
Potential Dangers of Serum Urate-Lowering Therapy.
Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study.
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Rasburicase treatment in severe tophaceous gout: a novel therapeutic option.
Recent insights into the pathogenesis of hyperuricaemia and gout.
Recombinant production of Aspergillus Flavus uricase and investigation of its thermal stability in the presence of raffinose and lactose.
Serum Urate, Uricase, and Blood Pressure Control in Gout.
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Site-specific incorporation of unnatural amino acids into urate oxidase in Escherichia coli.
Spatial Confined Synergistic Enzymes with Enhanced Uricolytic Performance and Reduced Toxicity for Effective Gout Treatment.
Strengthening the stability of a tunnel-shaped homotetramer protein with nanogels.
Structural and biochemical insights into a hyperthermostable urate oxidase from Thermobispora bispora for hyperuricemia and gout therapy.
Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol.
The case for uricase in gout.
The emerging role of biotechnological drugs in the treatment of gout.
Therapeutic approaches in the treatment of gout.
Thermostable and Long-Circulating Albumin-Conjugated Arthrobacter globiformis Urate Oxidase.
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.
Treatment of gout patients with impairment of renal function: a systematic literature review.
Urate crystal degradation for treatment of gout: a nanoparticulate combination therapy approach.
Urate oxidase (rasburicase) for treatment of severe acute gout: a case report.
Urate oxidase (rasburicase) for treatment of severe tophaceous gout.
Uricase and other novel agents for the management of patients with treatment-failure gout.
Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
Uricase production by a recombinant Hansenula polymorpha strain harboring Candida utilis uricase gene.
Uricases as therapeutic agents to treat refractory gout: Current states and future directions.
[Circadian rhythm of uric acid levels of the serum in gout]
[Current management of gout].
[Gout: an overview of available urate lowering therapies].
[Gout]
[Modalities of purine excretion during enzyme treatment of gout and other hyperuricemic conditions with urate oxidase]
[New antihyperuricemic medicine: febuxostat, Puricase, etc]
[New trend in gout treatment. Clinical and biological study of urate oxidase]
[Rasburicase (Fasturtec)]
[Rasburicase for tophaceus gout treatment]
[Recent advances in gout: pathogenesis, diagnosis, comorbidities, treatment].
[Urate oxidase in the treatment of gout and hyperuricemia]
Graft vs Host Disease
Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.
Heart Failure
Effect of uric acid lowering therapy on the prevention of acute kidney injury in cardiovascular surgery.
Hematologic Neoplasms
A radiochemical-high-performance liquid chromatographic assay for urate oxidase in human plasma.
A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase.
Challenges in the management of Burkitt's lymphoma.
Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies.
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Current management of gout in patients unresponsive or allergic to allopurinol.
Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies.
Efficacy and (pharmaco)kinetics of one single dose of rasburicase in patients with chronic kidney disease.
Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome.
Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies.
Low-dose Rasburicase in Hematologic Malignancies.
Methemoglobinemia induced by rasburicase in a pediatric patient: A case report and literature review.
Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.
Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).
Prevention and treatment of hyperuricemia in hematological malignancies.
Rasburicase for the treatment and prevention of hyperuricemia.
Rasburicase for the treatment of tumor lysis in hematological malignancies.
Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6-Phosphate Dehydrogenase Deficiency.
Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.
Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies.
Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea.
Recombinant urate oxidase (rasburicase): a new targeted therapy for prophylaxis and treatment of patients with hematologic malignancies at risk of tumor lysis syndrome.
Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience.
SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome.
[Analysis and protocolization of rasburicase use in patients with hematologic neoplasms]
[Effect of the Administration Period of Rasburicase in Japanese Adult Hematological Malignancy Patients at High-Risk for Tumor Lysis Syndrome].
Hemolytic-Uremic Syndrome
Rasburicase for hyperuricemia in hemolytic uremic syndrome.
Rasburicase improves the outcome of acute kidney injury from typical hemolytic uremic syndrome.
Rasburicase in hemolytic uremic syndrome related to Shiga toxin-producing Escherichia coli: a report of nine cases.
Hemophilia A
Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies.
Hepatitis B
Gateways to clinical trials.
Hepatitis C
Acute and severe ribavirin-associated hyperuricemia and acute kidney injury: An underrecognized adverse effect.
Gateways to clinical trials.
Severe Interferon/Ribavirin-Induced Hyperuricemia and Urate Nephropathy Requiring Rasburicase and Hemodialysis in a Liver Transplant Recipient.
Hepatomegaly
Deficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in mice.
Peroxisome proliferation and induction of peroxisomal enzymes in mouse and rat liver by dehydroepiandrosterone feeding.
The hypolipidemic peroxisome-proliferating drug, bis(carboxymethylthio)-1.10 decane, a dicarboxylic metabolite of tiadenol, is activated to an acylcoenzyme A thioester.
Hyperkalemia
[The pathophysiology, clinical signs and therapy of urate nephropathy]
Hyperphosphatemia
Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.
Hypersensitivity
A Case of Type 2 Hypersensitivity to Rasburicase Diagnosed with a Natural Killer Cell Activation Assay.
A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Management of hyperuricemia with rasburicase review.
Purification, quantification and gene expression of urate oxidases in rust-infected bean leaves.
Rasburicase : a review of its use in the management of anticancer therapy-induced hyperuricaemia.
Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study.
Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome.
Spotlight on rasburicase in anticancer therapy-induced hyperuricemia.
Structure-Based Immunogenicity Prediction of Uricase from Fungal (Aspergillus flavus), Bacterial (Bacillus subtillis) and Mammalian Sources Using Immunoinformatic Approach.
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies.
Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.
[Rasburicase for tophaceus gout treatment]
Hypertension
A role for uric acid in the progression of renal disease.
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Hyperuricemia, urate deposition and the association with hypertension.
Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders.
Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?
Rasburicase improves the outcome of acute kidney injury from typical hemolytic uremic syndrome.
Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia.
Synergistic effect of uricase blockade plus physiological amounts of fructose-glucose on glomerular hypertension and oxidative stress in rats.
Time to target uric acid to retard CKD progression.
Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.
Uric acid: bystander or culprit in hypertension and progressive renal disease?
Infections
Acute and severe ribavirin-associated hyperuricemia and acute kidney injury: An underrecognized adverse effect.
Effect of rust infection on levels of uricase, allantoinase and ureides in susceptible and hypersensitive bean leaves.
Expression pattern of uricase II gene during root nodule development in Phaseolus vulgaris.
Immunogold localization of nodule-specific uricase in developing soybean root nodules.
Purification, quantification and gene expression of urate oxidases in rust-infected bean leaves.
Influenza, Human
Gateways to clinical trials.
Insulin Resistance
Uric acid: bystander or culprit in hypertension and progressive renal disease?
Iron Deficiencies
Chromium toxicity in Neurospora crassa.
Kidney Calculi
EFFICACY OF RASBURICASE THERAPY IN OBSTRUCTIVE NEPHROPATHY FROM RENAL CALCULI: A NOVEL THERAPEUTIC OPTION.
Uric acid kidney stones induced in rats by oxonic acid, a uricase inhibitor.
Kidney Failure, Chronic
Expansion of Urease- and Uricase-Containing, Indole- and p-Cresol-Forming and Contraction of Short-Chain Fatty Acid-Producing Intestinal Microbiota in ESRD.
Interference in colorimetric reactions for measuring hydrogen peroxide.
Leishmaniasis
Peroxisomal function is altered during leishmania infection.
Lesch-Nyhan Syndrome
Efficacy of rasburicase in hyperuricemia secondary to Lesch-Nyhan syndrome.
[Treatment of high urinary xanthine excretion with increased amounts of allopurinol and with urate oxidase in a child with Lesch-Nyhan syndrome (author's transl)]
Leukemia
A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
Complications of "Very High" Leukocytosis in Pediatric Acute Leukemia Patients Managed Without Rasburicase and Leukopheresis.
Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial.
Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
Management of Hyperleukocytosis in Childhood Acute Leukemia Without Leukapheresis and Rasburicase Prophylaxis.
Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia.
Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
Recent advances in pediatric acute lymphoblastic and myeloid leukemia.
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.
Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series.
Treatment of impending tumor lysis with single-dose rasburicase.
[Anaphylaxis-like manifestations after intravenous injection of urate oxidase in an asthmatic child with acute leukemia]
[Anuria with hyperuricemia revealing acute leukemia. Treatment with urate oxidase]
Leukemia, Lymphocytic, Chronic, B-Cell
Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase.
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Leukemia, Myeloid, Acute
Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Risk factors for tumor lysis syndrome in childhood acute myeloid leukemia treated with a uniform protocol without rasburicase prophylaxis.
Leukocytosis
Complications of "Very High" Leukocytosis in Pediatric Acute Leukemia Patients Managed Without Rasburicase and Leukopheresis.
Experimental meningitis in the rat: protection by uric acid at human physiological blood concentrations.
Liver Neoplasms
[Uricase studies of rats in the course of liver cancer production.]
Lymphoma
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial.
Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review.
Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
Recent advances in pediatric acute lymphoblastic and myeloid leukemia.
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.
Lymphoma, Non-Hodgkin
Acute neurotoxicity as a serious adverse event related to rasburicase in a non-Hodgkin's lymphoma patient.
Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
European experience in the treatment of hyperuricemia.
Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies.
Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.
Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.
Malaria
Gateways to clinical trials.
Malaria, Vivax
Reference and point-of-care testing for G6PD deficiency: Blood disorder interference, contrived specimens, and fingerstick equivalence and precision.
Meningitis
Gateways to clinical trials.
Menkes Kinky Hair Syndrome
Urate oxidase activity and copper content in the liver of macular mutant mouse, a model animal for human congenital copper deficiency, Menkes' kinky hair disease.
Mesothelioma
Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies.
Metabolic Syndrome
Synergistic effect of uricase blockade plus physiological amounts of fructose-glucose on glomerular hypertension and oxidative stress in rats.
Uric acid as a modulator of glucose and lipid metabolism.
Uric acid: bystander or culprit in hypertension and progressive renal disease?
Methemoglobinemia
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.
Distinct mechanisms for rasburicase induced hemolytic anemia and methemoglobinemia in tumor lysis syndrome.
Exchange transfusion as treatment for rasburicase induced methemoglobinemia in a glucose-6-phosphate dehydrogenase deficient patient.
Hemolysis and methemoglobinemia secondary to rasburicase administration.
Inherited catalase deficiency: Is it benign or a factor in various age related disorders?
Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase.
Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia.
Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemia.
Methemoglobinemia induced by rasburicase in a pediatric patient: A case report and literature review.
Methemoglobinemia secondary to rasburicase in cancer: Non drug-related oxidative stress.
Rasburicase (Elitek): a novel agent for tumor lysis syndrome.
Rasburicase Causing Severe Oxidative Hemolysis and Methemoglobinemia in a Patient with Previously Unrecognized Glucose-6-Phosphate Dehydrogenase Deficiency.
Rasburicase induced severe hemolysis and methemoglobinemia in a Caucasian patient complicated by acute renal failure and ARDS.
Rasburicase-induced haemolysis and methemoglobinemia: an ongoing issue.
Rasburicase-induced Hemolytic Anemia in an Adolescent With Unknown Glucose-6-Phosphate Dehydrogenase Deficiency.
Rasburicase-Induced Methemoglobinemia in a Patient with Aggressive Non-Hodgkin's Lymphoma.
Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6-Phosphate Dehydrogenase Deficiency.
Rasburicase-induced methemoglobinemia in two African-American female patients: an under-recognized and continued problem.
Rasburicase-Induced Methemoglobinemia.
Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.
Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm.
Spotlight on rasburicase in anticancer therapy-induced hyperuricemia.
Mucositis
Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia.
Multiple Myeloma
Carfilzomib-Associated Tumor Lysis Syndrome.
Myeloproliferative Disorders
Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient.
Transient myeloproliferative disorder in a newborn with Down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: a case report.
Neoplasm Metastasis
Brief report: The uricase mutation in humans increases our risk for cancer growth.
Neoplasms
A Case of Spontaneous Tumor Lysis Syndrome in Malignant Melanoma.
A Case of Type 2 Hypersensitivity to Rasburicase Diagnosed with a Natural Killer Cell Activation Assay.
A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase.
A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.
A retrospective observational study of a low fixed-dose rasburicase protocol for the treatment of tumor lysis syndrome in adults.
A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.
A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function.
A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy.
A single, fixed dose of Rasburicase (6 mg maximum) for Treatment of Tumor Lysis Syndrome in Adults.
A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndrome.
Acute renal failure from xanthine nephropathy during management of acute leukemia.
Acute spontaneous tumor lysis syndrome in a patient with Crohn's disease taking immunosuppressants.
Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase.
Allantoin reduces cell death induced by cisplatin: possible implications for tumor lysis syndrome management.
Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase.
Assessment of rasburicase utilization for tumor lysis syndrome management in pediatric and adult patients in the inpatient and outpatient settings.
Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature.
B-cell lymphoma presenting with renal failure associated to spontaneous tumor lysis syndrome and urinary tract obstruction.
Brief report: The uricase mutation in humans increases our risk for cancer growth.
Catalase deficiency may complicate urate oxidase (rasburicase) therapy.
Clarifying the role of rasburicase in tumor lysis syndrome.
Cloning, expression and purification of recombinant uricase enzyme from Pseudomonas aeruginosa Ps43 using Escherichia coli.
Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
Computational Approach for Rational Design of Fusion Uricase with PAS Sequences.
Concurrent acute spontaneous tumor lysis syndrome complicated with multiple organ failure in a patient with pre-existing undiagnosed lung cancer.
Consensus conference on the management of tumor lysis syndrome.
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome.
Decreasing Inappropriate Use of Rasburicase to Promote Cost-Effective Care.
Deficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in mice.
Designing and Engineering of a Site-specific Incorporation of a Keto Group in Uricase.
Distinct mechanisms for rasburicase induced hemolytic anemia and methemoglobinemia in tumor lysis syndrome.
Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients.
Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome.
Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia.
Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase.
Effectiveness of a single fixed dose of rasburicase 3mg in the management of tumour lysis syndrome.
Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial.
Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy.
EFFICACY OF RASBURICASE THERAPY IN OBSTRUCTIVE NEPHROPATHY FROM RENAL CALCULI: A NOVEL THERAPEUTIC OPTION.
Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome.
Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy.
Efficient purification of a recombinant tag-free thermostable Kluyveromyces marxianus uricase by pH-induced self-cleavage of intein and expression in Escherichia coli.
Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.
Emerging therapies in the long-term management of hyperuricaemia and gout.
Enhancement of Pharmaceutical Urate Oxidase Thermostability by Rational Design of De Novo Disulfide Bridge.
Erythrocyte hemighosts in a patient with tumor lysis syndrome: One train may hide another.
European experience in the treatment of hyperuricemia.
Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer.
Evaluation of Rasburicase Use in the Fraser Health Authority: A Retrospective Review.
Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
Evolutionary history and metabolic insights of ancient mammalian uricases.
Excessive elevation of serum phosphate during tumor lysis syndrome: Lessons from a particularly challenging case.
Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Fixed-Dose Rasburicase in Overweight and Obese Patients Versus Normal-Weight Patients.
Heterologous expression of recombinant urate oxidase using the intein-mediated protein purification in Pichia pastoris.
Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis.
Hyperxanthinemia interferes with serum uric acid determinations by the uricase method.
I.V. ascorbic acid for treatment of apparent rasburicase-induced methemoglobinemia in a patient with acute kidney injury and assumed glucose-6-phosphate dehydrogenase deficiency.
Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies?
Management of Hyperleukocytosis in Childhood Acute Leukemia Without Leukapheresis and Rasburicase Prophylaxis.
Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review.
Management of tumour lysis syndrome in children: what is the evidence for prophylactic rasburicase in non-hyperleucocytic leukaemia?
Mathematical modeling for bioprocess optimization of a protein drug, uricase, production by Aspergillus welwitschiae strain 1-4.
Metastatic testicular cancer presenting with liver and kidney dysfunction treated with modified BEP chemotherapy combined with continuous hemodiafiltration and rasburicase.
Methemoglobinemia induced by rasburicase in a pediatric patient: A case report and literature review.
Methemoglobinemia secondary to rasburicase in cancer: Non drug-related oxidative stress.
One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies.
Oxidoreductase activities in normal rat liver, tumor-bearing rat liver, and hepatoma HC-252.
Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
Peroxisomal enzymes in normal and tumoral human breast.
Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).
Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?
Prevention and treatment of hyperuricemia in hematological malignancies.
Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.
Protective effect of urate oxidase on uric acid induced-monocyte apoptosis.
Rare Case of Transcutaneous Oxygen Desaturation in a Cancer Patient: A Case Report and Diagnostic Approach for a Recurrent Problem.
Rasburicase (Elitek): a novel agent for tumor lysis syndrome.
Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration.
Rasburicase Causing Severe Oxidative Hemolysis and Methemoglobinemia in a Patient with Previously Unrecognized Glucose-6-Phosphate Dehydrogenase Deficiency.
Rasburicase for huge hepatocellular carcinoma with tumor lysis syndrome: case report.
Rasburicase for prevention of hyperuricemia and tumor lysis syndrome.
Rasburicase for the management of tumor lysis syndrome in neonates.
Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
Rasburicase for the treatment of tumor lysis in hematological malignancies.
Rasburicase for Tumor Lysis Syndrome.
Rasburicase improves hyperuricemia in infants with acute kidney injury.
Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy.
Rasburicase in the prevention and treatment of tumour lysis syndrome.
Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
Rasburicase in Tumor Lysis Syndrome of the Adult: A Systematic Review and Meta-analysis.
Rasburicase induced severe hemolysis and methemoglobinemia in a Caucasian patient complicated by acute renal failure and ARDS.
Rasburicase prevents tumor lysis syndrome despite extreme hyperleukocytosis.
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Rasburicase-induced haemolysis and methemoglobinemia: an ongoing issue.
Rasburicase-induced Hemolytic Anemia in an Adolescent With Unknown Glucose-6-Phosphate Dehydrogenase Deficiency.
Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6-Phosphate Dehydrogenase Deficiency.
Rasburicase-induced methemoglobinemia in two African-American female patients: an under-recognized and continued problem.
Rasburicase-Induced Methemoglobinemia.
Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.
Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm.
Rasburicase-induced methemoglobinemia: The eyes do not see what the mind does not know.
Rasburicase.
Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome.
Rasburicase: a potent uricolytic agent.
Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome.
Rasburicase: future directions in tumor lysis management.
Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies.
Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Recent advances in pediatric acute lymphoblastic and myeloid leukemia.
Recombinant production of Aspergillus Flavus uricase and investigation of its thermal stability in the presence of raffinose and lactose.
Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial.
Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome.
Recombinant urate oxidase (rasburicase): a new targeted therapy for prophylaxis and treatment of patients with hematologic malignancies at risk of tumor lysis syndrome.
Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience.
Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.
Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy.
Reference and point-of-care testing for G6PD deficiency: Blood disorder interference, contrived specimens, and fingerstick equivalence and precision.
Refrigeration is not necessary for measurement of uric acid in patients treated with rasburicase.
Renal Calculi: An Unusual Presentation of T-Cell Acute Lymphoblastic Leukemia.
Review of the Literature Examining the Association of Serum Uric Acid with Osteoporosis and Mechanistic Insights into Its Effect on Bone Metabolism.
Risk factors for tumor lysis syndrome in childhood acute myeloid leukemia treated with a uniform protocol without rasburicase prophylaxis.
Role of i.v. allopurinol and rasburicase in tumor lysis syndrome.
Sampling on ice will not yield reliable uric acid monitoring in rasburicase-treated patients.
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
Single 4.5?mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
Single 6-mg dose of rasburicase: The experience in a large academic medical center.
Single dose of rasburicase for treatment of hyperuricemia in acute kidney injury: a report of 3 cases.
Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series.
Single dose Rasburicase is a clinically effective pharmacoeconomic approach for preventing tumour lysis syndrome in children with high tumour burden.
Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
Spontaneous Tumor Lysis Syndrome in Blastoid-Variant Mantle Cell Lymphoma: Considerations for the General Internist.
Strengthening the stability of a tunnel-shaped homotetramer protein with nanogels.
Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome.
T-Cell Lymphoblastic Lymphoma Presenting as Acute Clavicular Pain.
The Effective Control of Hyperuricemia in Cancer Patients: A New Recombinant Conjugated Variant of Urate Oxidase.
The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis.
The prevention of acute kidney injury an in-depth narrative review: Part 2: Drugs in the prevention of acute kidney injury.
The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome.
Therapeutic perspectives on uricases for gout.
Thermostable and Long-Circulating Albumin-Conjugated Arthrobacter globiformis Urate Oxidase.
Things We Do for No Reason™: Rasburicase for Adult Patients With Tumor Lysis Syndrome.
Transient myeloproliferative disorder in a newborn with Down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: a case report.
Treatment and prevention of tumor lysis syndrome in children. Experience of Associazione Italiana Ematologia Oncologia Pediatrica.
Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.
Treatment of impending tumor lysis with single-dose rasburicase.
Treatment of tumor lysis syndrome in children with leukemia/lymphoma in resource-limited settings-Efficacy of a fixed low-dose rasburicase.
Tumor Lysis Syndrome after Hepatic Artery Embolization in a Patient with Neuroendocrine Tumor of Unknown Primary.
Tumor lysis syndrome following cabazitaxel administration for metastatic castration-resistant prostate cancer: A case report.
Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature.
Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies.
Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.
Urate oxidase should remain mandatory in patients at high risk of tumor lysis syndrome.
Uric acid promotes tumor immune rejection.
Uricase production by a recombinant Hansenula polymorpha strain harboring Candida utilis uricase gene.
Use of rasburicase in a pregnant woman with acute lymphoblastic leukaemia and imminent tumour lysis syndrome.
Use of single-dose rasburicase in an obese female.
Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
Utilizing intein-mediated protein cleaving for purification of uricase, a multimeric enzyme.
[Analysis and protocolization of rasburicase use in patients with hematologic neoplasms]
[Effect of the Administration Period of Rasburicase in Japanese Adult Hematological Malignancy Patients at High-Risk for Tumor Lysis Syndrome].
[Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome]
[Role of uric acid in hypertension and in the progression of chronic renal disease.]
[Single-dose rasburicase as treatment for tumor lysis syndrome in two patients]
[The current status of the treatment of tumor lysis syndrome--the role of rasburicase (Fasturtec)]
[Tumor lysis syndrome: risk factors and treatment]
[Tumor lysis syndrome]
Neuroinflammatory Diseases
Targeting Uric Acid Prevents Brain Injury and Anxiety in a Rat Model of Hemorrhagic Shock.
Obesity
Perspective: A Historical and Scientific Perspective of Sugar and Its Relation with Obesity and Diabetes.
Redefining metabolic syndrome as a fat storage condition based on studies of comparative physiology.
Uric acid: a danger signal from the RNA world that may have a role in the epidemic of obesity, metabolic syndrome, and cardiorenal disease: evolutionary considerations.
Overweight
Fixed-Dose Rasburicase in Overweight and Obese Patients Versus Normal-Weight Patients.
Single 4.5?mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
Pancreatitis
Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions.
Revisiting the reported signal of acute pancreatitis with rasburicase: an object lesson in pharmacovigilance.
Pancytopenia
Urate oxidase (rasburicase) for treatment of severe acute gout: a case report.
Parasitic Diseases
Peroxisomal function is altered during leishmania infection.
Pneumonia
Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis.
Pneumonia, Bacterial
Acute and severe ribavirin-associated hyperuricemia and acute kidney injury: An underrecognized adverse effect.
Polyuria
EFFICACY OF RASBURICASE THERAPY IN OBSTRUCTIVE NEPHROPATHY FROM RENAL CALCULI: A NOVEL THERAPEUTIC OPTION.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia.
European experience in the treatment of hyperuricemia.
Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia.
Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.
Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series.
Treatment of impending tumor lysis with single-dose rasburicase.
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies.
Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.
Prostatic Neoplasms
Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer.
Proteinuria
Rasburicase improves the outcome of acute kidney injury from typical hemolytic uremic syndrome.
Pruritus
A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Renal Insufficiency
Acute spontaneous tumor lysis syndrome in a patient with Crohn's disease taking immunosuppressants.
Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature.
B-cell lymphoma presenting with renal failure associated to spontaneous tumor lysis syndrome and urinary tract obstruction.
Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
Degradation of low molecular weight uremic solutes by oral delivery of encapsulated enzymes.
EFFICACY OF RASBURICASE THERAPY IN OBSTRUCTIVE NEPHROPATHY FROM RENAL CALCULI: A NOVEL THERAPEUTIC OPTION.
Hyperuricemia and renal insufficiency associated with malignant disease: urate oxidase as an efficient therapy?
Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.
Managing malignancy-associated hyperuricemia with rasburicase.
Metastatic gestational trophoblastic neoplasia complicated by tumor lysis syndrome, heart failure, and thyrotoxicosis: a case report.
Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).
Protective effect of urate oxidase on uric acid induced-monocyte apoptosis.
Rasburicase improves hyperuricemia in patients with acute kidney injury secondary to rhabdomyolysis caused by ecstasy intoxication and exertional heat stroke.
Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
Rasburicase-induced methemoglobinemia: The eyes do not see what the mind does not know.
Rasburicase.
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series.
Treatment of gout patients with impairment of renal function: a systematic literature review.
Urate oxidase (rasburicase) for treatment of severe acute gout: a case report.
Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.
[Acute hyperleukocytic lymphoblastic leukemia (greater than or equal to 100,000 leukocytes/mm3). Metabolic changes during induction treatment. Study, prevention and treatment]
[Influence of renal insufficiency on the pharmokinetics and metabolism of urate oxidase]
[Letter: Acute hyperuricemic kidney failure. Treatment by uricozyme]
Renal Insufficiency, Chronic
A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.
Efficacy and (pharmaco)kinetics of one single dose of rasburicase in patients with chronic kidney disease.
Pharmacokinetics and pharmacodynamics of pegloticase in patients with end-stage renal failure receiving hemodialysis.
Respiratory Insufficiency
Rasburicase-induced haemolysis and methemoglobinemia: an ongoing issue.
Rhabdomyolysis
Rasburicase improves hyperuricemia in patients with acute kidney injury secondary to rhabdomyolysis caused by ecstasy intoxication and exertional heat stroke.
Seizures
Disruption, but not overexpression of urate oxidase alters susceptibility to pentylenetetrazole- and pilocarpine-induced seizures in mice.
Uric acid is released in the brain during seizure activity and increases severity of seizures in a mouse model for acute limbic seizures.
Starvation
An electron microscopic and enzymic study of rat liver peroxisomal nucleoid core and its association with urate oxidase.
Earliest evidence of caries lesion in hominids reveal sugar-rich diet for a Middle Miocene dryopithecine from Europe.
Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids.
Stroke
Rasburicase improves hyperuricemia in patients with acute kidney injury secondary to rhabdomyolysis caused by ecstasy intoxication and exertional heat stroke.
Testicular Neoplasms
Metastatic testicular cancer presenting with liver and kidney dysfunction treated with modified BEP chemotherapy combined with continuous hemodiafiltration and rasburicase.
Thrombocytopenia
Complications of "Very High" Leukocytosis in Pediatric Acute Leukemia Patients Managed Without Rasburicase and Leukopheresis.
Tumor Lysis Syndrome
A Case of Spontaneous Tumor Lysis Syndrome in Malignant Melanoma.
A Case of Type 2 Hypersensitivity to Rasburicase Diagnosed with a Natural Killer Cell Activation Assay.
A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase.
A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.
A retrospective observational study of a low fixed-dose rasburicase protocol for the treatment of tumor lysis syndrome in adults.
A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.
A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function.
A single, fixed dose of Rasburicase (6 mg maximum) for Treatment of Tumor Lysis Syndrome in Adults.
A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndrome.
Acute renal failure from xanthine nephropathy during management of acute leukemia.
Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase.
Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase.
Assessment of rasburicase utilization for tumor lysis syndrome management in pediatric and adult patients in the inpatient and outpatient settings.
Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature.
B-cell lymphoma presenting with renal failure associated to spontaneous tumor lysis syndrome and urinary tract obstruction.
Catalase deficiency may complicate urate oxidase (rasburicase) therapy.
Clarifying the role of rasburicase in tumor lysis syndrome.
Cloning, expression and purification of recombinant uricase enzyme from Pseudomonas aeruginosa Ps43 using Escherichia coli.
Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
Computational Approach for Rational Design of Fusion Uricase with PAS Sequences.
Consensus conference on the management of tumor lysis syndrome.
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome.
Decreasing Inappropriate Use of Rasburicase to Promote Cost-Effective Care.
Designing and Engineering of a Site-specific Incorporation of a Keto Group in Uricase.
Distinct mechanisms for rasburicase induced hemolytic anemia and methemoglobinemia in tumor lysis syndrome.
Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients.
Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome.
Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase.
Effectiveness of a single fixed dose of rasburicase 3mg in the management of tumour lysis syndrome.
Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
EFFICACY OF RASBURICASE THERAPY IN OBSTRUCTIVE NEPHROPATHY FROM RENAL CALCULI: A NOVEL THERAPEUTIC OPTION.
Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome.
Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
Efficient purification of a recombinant tag-free thermostable Kluyveromyces marxianus uricase by pH-induced self-cleavage of intein and expression in Escherichia coli.
Emerging therapies in the long-term management of hyperuricaemia and gout.
Erythrocyte hemighosts in a patient with tumor lysis syndrome: One train may hide another.
European experience in the treatment of hyperuricemia.
Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer.
Evaluation of Rasburicase Use in the Fraser Health Authority: A Retrospective Review.
Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
Evolutionary history and metabolic insights of ancient mammalian uricases.
Excessive elevation of serum phosphate during tumor lysis syndrome: Lessons from a particularly challenging case.
Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Fixed-Dose Rasburicase in Overweight and Obese Patients Versus Normal-Weight Patients.
Heterologous expression of recombinant urate oxidase using the intein-mediated protein purification in Pichia pastoris.
Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies?
Management of Hyperleukocytosis in Childhood Acute Leukemia Without Leukapheresis and Rasburicase Prophylaxis.
Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review.
Management of tumour lysis syndrome in children: what is the evidence for prophylactic rasburicase in non-hyperleucocytic leukaemia?
Metastatic testicular cancer presenting with liver and kidney dysfunction treated with modified BEP chemotherapy combined with continuous hemodiafiltration and rasburicase.
Methemoglobinemia induced by rasburicase in a pediatric patient: A case report and literature review.
One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies.
Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).
Prevention and treatment of hyperuricemia in hematological malignancies.
Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.
Rare Case of Transcutaneous Oxygen Desaturation in a Cancer Patient: A Case Report and Diagnostic Approach for a Recurrent Problem.
Rasburicase (Elitek): a novel agent for tumor lysis syndrome.
Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration.
Rasburicase Causing Severe Oxidative Hemolysis and Methemoglobinemia in a Patient with Previously Unrecognized Glucose-6-Phosphate Dehydrogenase Deficiency.
Rasburicase for huge hepatocellular carcinoma with tumor lysis syndrome: case report.
Rasburicase for prevention of hyperuricemia and tumor lysis syndrome.
Rasburicase for the management of tumor lysis syndrome in neonates.
Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
Rasburicase for Tumor Lysis Syndrome.
Rasburicase in the prevention and treatment of tumour lysis syndrome.
Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
Rasburicase in Tumor Lysis Syndrome of the Adult: A Systematic Review and Meta-analysis.
Rasburicase induced severe hemolysis and methemoglobinemia in a Caucasian patient complicated by acute renal failure and ARDS.
Rasburicase prevents tumor lysis syndrome despite extreme hyperleukocytosis.
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Rasburicase-induced haemolysis and methemoglobinemia: an ongoing issue.
Rasburicase-induced Hemolytic Anemia in an Adolescent With Unknown Glucose-6-Phosphate Dehydrogenase Deficiency.
Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6-Phosphate Dehydrogenase Deficiency.
Rasburicase-induced methemoglobinemia in two African-American female patients: an under-recognized and continued problem.
Rasburicase-Induced Methemoglobinemia.
Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.
Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm.
Rasburicase-induced methemoglobinemia: The eyes do not see what the mind does not know.
Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome.
Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome.
Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Recent advances in pediatric acute lymphoblastic and myeloid leukemia.
Recombinant production of Aspergillus Flavus uricase and investigation of its thermal stability in the presence of raffinose and lactose.
Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome.
Recombinant urate oxidase (rasburicase): a new targeted therapy for prophylaxis and treatment of patients with hematologic malignancies at risk of tumor lysis syndrome.
Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience.
Refrigeration is not necessary for measurement of uric acid in patients treated with rasburicase.
Renal Calculi: An Unusual Presentation of T-Cell Acute Lymphoblastic Leukemia.
Risk factors for tumor lysis syndrome in childhood acute myeloid leukemia treated with a uniform protocol without rasburicase prophylaxis.
Role of i.v. allopurinol and rasburicase in tumor lysis syndrome.
Sampling on ice will not yield reliable uric acid monitoring in rasburicase-treated patients.
SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
Single 4.5?mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
Single 6-mg dose of rasburicase: The experience in a large academic medical center.
Single dose of rasburicase for treatment of hyperuricemia in acute kidney injury: a report of 3 cases.
Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series.
Single dose Rasburicase is a clinically effective pharmacoeconomic approach for preventing tumour lysis syndrome in children with high tumour burden.
Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
Strengthening the stability of a tunnel-shaped homotetramer protein with nanogels.
Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome.
T-Cell Lymphoblastic Lymphoma Presenting as Acute Clavicular Pain.
The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis.
The prevention of acute kidney injury an in-depth narrative review: Part 2: Drugs in the prevention of acute kidney injury.
The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome.
Therapeutic perspectives on uricases for gout.
Thermostable and Long-Circulating Albumin-Conjugated Arthrobacter globiformis Urate Oxidase.
Things We Do for No Reason™: Rasburicase for Adult Patients With Tumor Lysis Syndrome.
Transient myeloproliferative disorder in a newborn with Down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: a case report.
Treatment and prevention of tumor lysis syndrome in children. Experience of Associazione Italiana Ematologia Oncologia Pediatrica.
Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.
Treatment of tumor lysis syndrome in children with leukemia/lymphoma in resource-limited settings-Efficacy of a fixed low-dose rasburicase.
Tumor Lysis Syndrome after Hepatic Artery Embolization in a Patient with Neuroendocrine Tumor of Unknown Primary.
Tumor lysis syndrome following cabazitaxel administration for metastatic castration-resistant prostate cancer: A case report.
Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature.
Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Urate oxidase should remain mandatory in patients at high risk of tumor lysis syndrome.
Uricase production by a recombinant Hansenula polymorpha strain harboring Candida utilis uricase gene.
Use of rasburicase in a pregnant woman with acute lymphoblastic leukaemia and imminent tumour lysis syndrome.
Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
Utilizing intein-mediated protein cleaving for purification of uricase, a multimeric enzyme.
[Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome]
[Role of uric acid in hypertension and in the progression of chronic renal disease.]
[Single-dose rasburicase as treatment for tumor lysis syndrome in two patients]
[Tumor lysis syndrome: risk factors and treatment]
[Tumor lysis syndrome]
Uremia
[Uricase therapy of alloxan uremia in pigeons.]
[Value of addition of a fungal urate oxidase to the dietary treatment of chronic uremia]
Urolithiasis
Dissolution of extensive urolithiasis: extending the utility of rasburicase can avoid the need for surgical intervention and renal replacement therapy.
Urticaria
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies.
Vascular Diseases
A role for uric acid in the progression of renal disease.
Ventilator-Induced Lung Injury
Pre-treatment with allopurinol or uricase attenuates barrier dysfunction but not inflammation during murine ventilator-induced lung injury.
Vitamin A Deficiency
Effects of vitamin A deficiency on selected xenobiotic-metabolizing enzymes and defenses against oxidative stress in mouse liver.